THYSSENKRUPP NUCERA AG & CO (NCH2.DE) Stock Fundamental Analysis
Europe • Frankfurt Stock Exchange • FRA:NCH2 • DE000NCA0001
9.18 EUR
+0.05 (+0.55%)
Last: Feb 3, 2026, 11:40 AM
Overall NCH2 gets a fundamental rating of 4 out of 10. We evaluated NCH2 against 42 industry peers in the Construction & Engineering industry. No worries on liquidiy or solvency for NCH2 as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, NCH2 is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- NCH2 had positive earnings in the past year.
- NCH2 had a positive operating cash flow in the past year.
- NCH2 had positive earnings in each of the past 5 years.
- The reported operating cash flow has been mixed in the past 5 years: NCH2 reported negative operating cash flow in multiple years.
1.2 Ratios
- NCH2's Return On Assets of 0.39% is on the low side compared to the rest of the industry. NCH2 is outperformed by 80.95% of its industry peers.
- The Return On Equity of NCH2 (0.61%) is worse than 83.33% of its industry peers.
- NCH2's Return On Invested Capital of 0.18% is on the low side compared to the rest of the industry. NCH2 is outperformed by 92.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.39% | ||
| ROE | 0.61% | ||
| ROIC | 0.18% |
ROA(3y)1.12%
ROA(5y)1.92%
ROE(3y)1.76%
ROE(5y)3.72%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Profit Margin, with a value of 0.54%, NCH2 is doing worse than 80.95% of the companies in the same industry.
- In the last couple of years the Profit Margin of NCH2 has declined.
- Looking at the Operating Margin, with a value of 0.30%, NCH2 is doing worse than 88.10% of the companies in the same industry.
- NCH2 has a worse Gross Margin (13.05%) than 85.71% of its industry peers.
- In the last couple of years the Gross Margin of NCH2 has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.3% | ||
| PM (TTM) | 0.54% | ||
| GM | 13.05% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-29.84%
PM growth 5Y-42.32%
GM growth 3Y-10.67%
GM growth 5Y-10.96%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so NCH2 is destroying value.
- Compared to 1 year ago, NCH2 has about the same amount of shares outstanding.
- The number of shares outstanding for NCH2 remains at a similar level compared to 5 years ago.
- The debt/assets ratio for NCH2 is higher compared to a year ago.
2.2 Solvency
- NCH2 has an Altman-Z score of 3.22. This indicates that NCH2 is financially healthy and has little risk of bankruptcy at the moment.
- NCH2's Altman-Z score of 3.22 is amongst the best of the industry. NCH2 outperforms 83.33% of its industry peers.
- NCH2 has a debt to FCF ratio of 2.61. This is a good value and a sign of high solvency as NCH2 would need 2.61 years to pay back of all of its debts.
- The Debt to FCF ratio of NCH2 (2.61) is better than 73.81% of its industry peers.
- A Debt/Equity ratio of 0.03 indicates that NCH2 is not too dependend on debt financing.
- The Debt to Equity ratio of NCH2 (0.03) is better than 97.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | 2.61 | ||
| Altman-Z | 3.22 |
ROIC/WACC0.02
WACC7.41%
2.3 Liquidity
- NCH2 has a Current Ratio of 2.68. This indicates that NCH2 is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of NCH2 (2.68) is better than 100.00% of its industry peers.
- A Quick Ratio of 2.20 indicates that NCH2 has no problem at all paying its short term obligations.
- NCH2 has a better Quick ratio (2.20) than 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.68 | ||
| Quick Ratio | 2.2 |
3. Growth
3.1 Past
- The earnings per share for NCH2 have decreased strongly by -66.67% in the last year.
- The earnings per share for NCH2 have been decreasing by -26.62% on average. This is quite bad
- The Revenue has decreased by -2.06% in the past year.
- The Revenue has been growing by 27.16% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-66.67%
EPS 3Y-8.6%
EPS 5Y-26.62%
EPS Q2Q%-100%
Revenue 1Y (TTM)-2.06%
Revenue growth 3Y30.18%
Revenue growth 5Y27.16%
Sales Q2Q%-27.12%
3.2 Future
- NCH2 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 109.64% yearly.
- Based on estimates for the next years, NCH2 will show a quite strong growth in Revenue. The Revenue will grow by 15.35% on average per year.
EPS Next Y-38.12%
EPS Next 2Y109.02%
EPS Next 3Y97.73%
EPS Next 5Y109.64%
Revenue Next Year-31.95%
Revenue Next 2Y-8.65%
Revenue Next 3Y-0.93%
Revenue Next 5Y15.35%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 306.00 indicates a quite expensive valuation of NCH2.
- Compared to the rest of the industry, the Price/Earnings ratio of NCH2 indicates a rather expensive valuation: NCH2 more expensive than 83.33% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 28.41, NCH2 is valued quite expensively.
- Based on the Price/Forward Earnings ratio of 494.51, the valuation of NCH2 can be described as expensive.
- Based on the Price/Forward Earnings ratio, NCH2 is valued more expensive than 88.10% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 25.64. NCH2 is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 306 | ||
| Fwd PE | 494.51 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, NCH2 is valued a bit more expensive than the industry average as 76.19% of the companies are valued more cheaply.
- Based on the Price/Free Cash Flow ratio, NCH2 is valued a bit more expensive than the industry average as 66.67% of the companies are valued more cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 107.36 | ||
| EV/EBITDA | 30.62 |
4.3 Compensation for Growth
- NCH2's earnings are expected to grow with 97.73% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y109.02%
EPS Next 3Y97.73%
5. Dividend
5.1 Amount
- NCH2 does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:NCH2 (2/3/2026, 11:40:08 AM)
9.18
+0.05 (+0.55%)
Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryConstruction & Engineering
Earnings (Last)11-24 2025-11-24/amc
Earnings (Next)02-11 2026-02-11
Inst Owners11.34%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.16B
Revenue(TTM)844.20M
Net Income(TTM)4.60M
Analysts76.67
Price Target10.58 (15.25%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-114.01%
Min EPS beat(2)-128.01%
Max EPS beat(2)-100%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-12.59%
Min Revenue beat(2)-12.74%
Max Revenue beat(2)-12.43%
Revenue beat(4)1
Avg Revenue beat(4)-5.04%
Min Revenue beat(4)-12.74%
Max Revenue beat(4)10.74%
Revenue beat(8)1
Avg Revenue beat(8)-5.14%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.87%
PT rev (3m)-13.21%
EPS NQ rev (1m)100%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-62.24%
EPS NY rev (3m)-86.44%
Revenue NQ rev (1m)1.74%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-22.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 306 | ||
| Fwd PE | 494.51 | ||
| P/S | 1.37 | ||
| P/FCF | 107.36 | ||
| P/OCF | 23.14 | ||
| P/B | 1.54 | ||
| P/tB | 1.73 | ||
| EV/EBITDA | 30.62 |
EPS(TTM)0.03
EY0.33%
EPS(NY)0.02
Fwd EY0.2%
FCF(TTM)0.09
FCFY0.93%
OCF(TTM)0.4
OCFY4.32%
SpS6.68
BVpS5.96
TBVpS5.32
PEG (NY)N/A
PEG (5Y)N/A
Graham Number2.01
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.39% | ||
| ROE | 0.61% | ||
| ROCE | 0.32% | ||
| ROIC | 0.18% | ||
| ROICexc | 1.49% | ||
| ROICexgc | 8.84% | ||
| OM | 0.3% | ||
| PM (TTM) | 0.54% | ||
| GM | 13.05% | ||
| FCFM | 1.28% |
ROA(3y)1.12%
ROA(5y)1.92%
ROE(3y)1.76%
ROE(5y)3.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-29.84%
PM growth 5Y-42.32%
GM growth 3Y-10.67%
GM growth 5Y-10.96%
F-Score6
Asset Turnover0.72
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | 2.61 | ||
| Debt/EBITDA | 1.52 | ||
| Cap/Depr | 295.49% | ||
| Cap/Sales | 4.66% | ||
| Interest Coverage | 1.92 | ||
| Cash Conversion | 317.09% | ||
| Profit Quality | 234.78% | ||
| Current Ratio | 2.68 | ||
| Quick Ratio | 2.2 | ||
| Altman-Z | 3.22 |
F-Score6
WACC7.41%
ROIC/WACC0.02
Cap/Depr(3y)192.94%
Cap/Depr(5y)124.39%
Cap/Sales(3y)2.25%
Cap/Sales(5y)1.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-66.67%
EPS 3Y-8.6%
EPS 5Y-26.62%
EPS Q2Q%-100%
EPS Next Y-38.12%
EPS Next 2Y109.02%
EPS Next 3Y97.73%
EPS Next 5Y109.64%
Revenue 1Y (TTM)-2.06%
Revenue growth 3Y30.18%
Revenue growth 5Y27.16%
Sales Q2Q%-27.12%
Revenue Next Year-31.95%
Revenue Next 2Y-8.65%
Revenue Next 3Y-0.93%
Revenue Next 5Y15.35%
EBIT growth 1Y117.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year315.25%
EBIT Next 3Y196.54%
EBIT Next 5Y112.41%
FCF growth 1Y114.4%
FCF growth 3Y-49.91%
FCF growth 5Y34.5%
OCF growth 1Y180.81%
OCF growth 3Y-16.84%
OCF growth 5Y63.58%
THYSSENKRUPP NUCERA AG & CO / NCH2.DE FAQ
What is the fundamental rating for NCH2 stock?
ChartMill assigns a fundamental rating of 4 / 10 to NCH2.DE.
What is the valuation status for NCH2 stock?
ChartMill assigns a valuation rating of 1 / 10 to THYSSENKRUPP NUCERA AG & CO (NCH2.DE). This can be considered as Overvalued.
What is the profitability of NCH2 stock?
THYSSENKRUPP NUCERA AG & CO (NCH2.DE) has a profitability rating of 2 / 10.
What is the valuation of THYSSENKRUPP NUCERA AG & CO based on its PE and PB ratios?
The Price/Earnings (PE) ratio for THYSSENKRUPP NUCERA AG & CO (NCH2.DE) is 306 and the Price/Book (PB) ratio is 1.54.
Can you provide the expected EPS growth for NCH2 stock?
The Earnings per Share (EPS) of THYSSENKRUPP NUCERA AG & CO (NCH2.DE) is expected to decline by -38.12% in the next year.